Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine on Brain Structure in Alzheimer's Disease
NCT00255086Phase 3Completed
- Sponsor
- Stanford University
- Start
- May 2005
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of memantine in Alzheimer's disease (AD) (2 arms), sponsored by Stanford University. Primary endpoint: N-acetylaspartate/Creatine Ratio at 1 year. Started May 2005; status: completed.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00255086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255086.